RxDoctor Payments Data

Harold Doll, MD

Nephrology · Tallahassee, FLNPI 1093717654

Payments from drug & device makers

$359in general payments, 2019–2025

Across 11 payments — averaging $32.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$141
  • Bayer$117
  • Aurinia Pharma U.S., Inc.$36
  • Lemaitre Vascular, Inc.$25
  • Akebia Therapeutics Inc$23
  • Boston Scientific$14
  • plus $3 from 1 others

What the payments were for

  • Food & beverage$32089%
  • Education$3911%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$359 in reported general payments places this provider in the 20th percentile of 756 nephrology providers in Florida.

See all nephrology providers in Florida

Medicare billing

Part B allowed, 2024
$199,995
Medicare patients
284
Services billed
949

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol99$103,893
JardianceEmpagliflozin31$41,736
VelphoroSucroferric Oxyhydroxide12$28,675
ProcritEpoetin Alfa23$25,490
VeltassaPatiromer Calcium Sorbitex20$24,137
RetacritEpoetin Alfa-Epbx54$22,489
JanuviaSitagliptin Phosphate12$17,137
EntrestoSacubitril/Valsartan11$16,235
Sevelamer Carbonate49$15,166
LokelmaSodium Zirconium Cyclosilicate13$10,006
KerendiaFinerenone14$8,476
ClinolipidFat Emulsion/Olive/Soy/Phospho45$6,760
BrilintaTicagrelor11$6,717
Cinacalcet Hcl23$6,605
Calcium Acetate57$5,085

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
BayerKerendia$117$8,47614 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 756 nephrology providers in Florida.

Other nephrology in Tallahassee

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →